When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
VRNA - Verona Pharma Is Launching Ohtuvayre Although There Will Be Competition
Verona Pharma plc
2024-06-30 09:00:00 ET
Summary
VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26.
SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from SNY/REGN and GSK.
Verona has the potential for further growth beyond the current approval, although in the near-term, initial sales seem likely to be a major determinant of the stock's direction.